Statement from FDA Commissioner Scott Gottlieb, M.D., on new policies to reduce the ability of brand drug makers to use REMS programs as a way to block timely generic drug entry, helping promote competition and access - FDA Press Releases

FDA Commissioner on new policies to reduce ability of brand drug makers to use REMS programs to block timely generic drug entry

from Food and Drug Administration--Press Releases https://ift.tt/2J0gt6R
via IFTTT